Chinese authorities said Wednesday it has completed the clinical research of “faviravir”, an antiviral drug proved to be effective in treating the novel coronavirus (COVID-19) patients.
“Avigan (Favipiravir), an anti-influenza drug approved for clinical use in Japan in 2014, had no obvious side effects in the clinical trials,” said Zhang Xinmin, China’s director of the National Center for Biotechnology Development, according to Xinhua News Agency.
The director said he formally recommended the use of this medicine as a way to treat the COVID-19 disease.
According to Zhang, a Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the medication and ensure a stable supply.
Source: Jordan News Agency